$Corbus Ph_老虎社区_美港股上老虎

大空翼_涨
2018-09-21

$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$

该公司宣布已获得Jenrin Discovery LLC公司600多种针对endocannabinoid系统的化合物在全球范围内的独家研发、生产和销售许可。该管道包括CRB-4001、Jenrin的第二代、外周受限、CB1逆激动剂靶向肝、肺、心脏和肾纤维化疾病。预计CRB-4001将于明年进入第一阶段测试。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

明晚七点秋名山
·2018-09-21
关键是还有大麻的概念大麻药物已经在使用中
回复
点赞
举报

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":275267,"tweetId":"275267","gmtCreate":1537513041727,"gmtModify":1704774476797,"author":{"id":133490453318800,"authorId":133490453318800,"authorIdStr":"133490453318800","name":"大空翼_涨","avatar":"https://static.laohu8.com/33bc959e4bc82c6e7ccda941a6702b4f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.29%","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":39,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ </p> 该公司宣布已获得Jenrin Discovery LLC公司600多种针对endocannabinoid系统的化合物在全球范围内的独家研发、生产和销售许可。 该管道包括CRB-4001、Jenrin的第二代、外周受限、CB1逆激动剂靶向肝、肺、心脏和肾纤维化疾病。预计CRB-4001将于明年进入第一阶段测试。</body></html>","htmlText":"<html><head></head><body><p>$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ </p> 该公司宣布已获得Jenrin Discovery LLC公司600多种针对endocannabinoid系统的化合物在全球范围内的独家研发、生产和销售许可。 该管道包括CRB-4001、Jenrin的第二代、外周受限、CB1逆激动剂靶向肝、肺、心脏和肾纤维化疾病。预计CRB-4001将于明年进入第一阶段测试。</body></html>","text":"$Corbus Pharmaceuticals Holdings, Inc.(CRBP)$ 该公司宣布已获得Jenrin Discovery LLC公司600多种针对endocannabinoid系统的化合物在全球范围内的独家研发、生产和销售许可。 该管道包括CRB-4001、Jenrin的第二代、外周受限、CB1逆激动剂靶向肝、肺、心脏和肾纤维化疾病。预计CRB-4001将于明年进入第一阶段测试。","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/275267","repostId":0,"isVote":1,"tweetType":1,"viewCount":1866,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["CRBP"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":276,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":1026502,"gmtCreate":1537516974161,"gmtModify":1537516974161,"authorId":238312778982404,"author":{"id":238312778982404,"authorId":238312778982404,"name":"明晚七点秋名山","avatar":"https://static.laohu8.com/0d51ca48fbac26c185fa14cfe814bb0e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":275267,"type":1,"supId":0,"prevId":0,"content":"关键是还有大麻的概念 大麻药物已经在使用中","text":"关键是还有大麻的概念 大麻药物已经在使用中","html":"关键是还有大麻的概念 大麻药物已经在使用中","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}

评论（1）

热议股票